Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 32

Related Articles by Review for PubMed (Select 19424940)

1.

Novel and evolving therapies in the treatment of malignant phaeochromocytoma: experience with the mTOR inhibitor everolimus (RAD001).

Druce MR, Kaltsas GA, Fraenkel M, Gross DJ, Grossman AB.

Horm Metab Res. 2009 Sep;41(9):697-702. doi: 10.1055/s-0029-1220687. Epub 2009 May 7.

PMID:
19424940
2.

The applicability of mTOR inhibition in solid tumors.

Konings IR, Verweij J, Wiemer EA, Sleijfer S.

Curr Cancer Drug Targets. 2009 May;9(3):439-50. Review.

PMID:
19442061
3.

mTOR inhibitors in the treatment of cancer.

Fasolo A, Sessa C.

Expert Opin Investig Drugs. 2008 Nov;17(11):1717-34. doi: 10.1517/13543784.17.11.1717 . Review.

PMID:
18922108
4.

The diagnosis and management of malignant phaeochromocytoma and paraganglioma.

Chrisoulidou A, Kaltsas G, Ilias I, Grossman AB.

Endocr Relat Cancer. 2007 Sep;14(3):569-85. Review.

5.

[Everolimus (RAD001) and solid tumours: a 2008 summary].

Lévy A, Sauvin LA, Massard C, Soria JC.

Bull Cancer. 2008 Dec;95(12):1205-11. doi: 10.1684/bdc.2008.0767. Review. French.

PMID:
19091655
6.

Current status and challenges associated with targeting mTOR for cancer therapy.

Dowling RJ, Pollak M, Sonenberg N.

BioDrugs. 2009;23(2):77-91. doi: 10.2165/00063030-200923020-00002. Review.

PMID:
19489650
7.

Mechanisms of mammalian target of rapamycin inhibition in sarcoma: present and future.

MacKenzie AR, von Mehren M.

Expert Rev Anticancer Ther. 2007 Aug;7(8):1145-54. Review.

PMID:
18028023
8.

Deforolimus (AP23573) a novel mTOR inhibitor in clinical development.

Mita M, Sankhala K, Abdel-Karim I, Mita A, Giles F.

Expert Opin Investig Drugs. 2008 Dec;17(12):1947-54. doi: 10.1517/13543780802556485 . Review.

PMID:
19012509
9.

Malignant pheochromocytomas and paragangliomas: molecular signaling pathways and emerging therapies.

Santarpia L, Habra MA, Jiménez C.

Horm Metab Res. 2009 Sep;41(9):680-6. doi: 10.1055/s-0029-1214381. Epub 2009 Apr 2. Review.

PMID:
19343618
10.

mTOR signalling in human cancer.

Albanell J, Dalmases A, Rovira A, Rojo F.

Clin Transl Oncol. 2007 Aug;9(8):484-93. Review.

PMID:
17720651
11.

Everolimus (RAD001): an mTOR inhibitor for the treatment of metastatic renal cell carcinoma.

Oudard S, Medioni J, Aylllon J, Barrascourt E, Elaidi RT, Balcaceres J, Scotte F.

Expert Rev Anticancer Ther. 2009 Jun;9(6):705-17. doi: 10.1586/era.09.27. Review.

PMID:
19496707
12.

[Mammalian target of rapamycin, its mode of action and clinical response in metastatic clear cell carcinoma].

Shuuin T, Karashima H.

Gan To Kagaku Ryoho. 2009 Jul;36(7):1076-9. Review. Japanese.

PMID:
19620795
13.

The PI3K/Akt/mTOR pathway as therapeutic target in neuroblastoma.

Fulda S.

Curr Cancer Drug Targets. 2009 Sep;9(6):729-37. Review.

PMID:
19754357
14.

alpha-Methyl-p-tyrosine: a review of its pharmacology and clinical use.

Brogden RN, Heel RC, Speight TM, Avery GS.

Drugs. 1981 Feb;21(2):81-9. Review.

PMID:
7009139
15.

Malignant phaeochromocytoma metastasising to the breast.

Shaw C, O'Hanlon DM, O'Keane C, Kerin MJ.

Ir J Med Sci. 2003 Jan-Mar;172(1):41-2. Review.

PMID:
12760464
16.

Update on tumours of the adrenal cortex, phaeochromocytoma and extra-adrenal paraganglioma.

McNicol AM.

Histopathology. 2011 Jan;58(2):155-68. doi: 10.1111/j.1365-2559.2010.03613.x. Epub 2010 Aug 16. Review.

PMID:
20718871
17.

The role of somatostatin analogues in the treatment of neuroendocrine tumours.

Grozinsky-Glasberg S, Grossman AB, Korbonits M.

Mol Cell Endocrinol. 2008 May 14;286(1-2):238-50. Epub 2007 Oct 13. Review.

PMID:
18037561
18.

Development of differential diagnosis for benign and malignant pheochromocytomas.

Gao B, Kong F, Xu Z.

Int J Urol. 2008 Sep;15(9):771-7. doi: 10.1111/j.1442-2042.2008.02111.x. Epub 2008 Jul 10. Review.

PMID:
18651863
19.

Pheochromocytomas, PASS, and immunohistochemistry.

Carlsen E, Abdullah Z, Kazmi SM, Kousparos G.

Horm Metab Res. 2009 Sep;41(9):715-9. doi: 10.1055/s-0029-1238274. Epub 2009 Aug 28. Review.

PMID:
19718615
20.

Malignant pheochromocytoma: current status and initiatives for future progress.

Eisenhofer G, Bornstein SR, Brouwers FM, Cheung NK, Dahia PL, de Krijger RR, Giordano TJ, Greene LA, Goldstein DS, Lehnert H, Manger WM, Maris JM, Neumann HP, Pacak K, Shulkin BL, Smith DI, Tischler AS, Young WF Jr.

Endocr Relat Cancer. 2004 Sep;11(3):423-36. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk